J
James A. Bonner
Researcher at University of Alabama at Birmingham
Publications - 252
Citations - 17463
James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.
Papers
More filters
Journal ArticleDOI
993pdassociation of human papillomavirus (hpv) and p16 status with efficacy and safety data in the phase iii radiotherapy (rt)/cetuximab (cet) registration trial for locoregionally advanced squamous cell carcinoma of the head and neck (lascchn)
James A. Bonner,Paul M. Harari,Jordi Giralt,Diana Bell,David Raben,J. Liu,Jeltje Schulten,Kian K. Ang,David I. Rosenthal +8 more
TL;DR: A subgroup analysis of the Bonner trial showed that the effect of adding cetuximab to RT on mucositis and dysphagia in patients with p16+ or p16− OPC was not affected, and p16 status has been widely used as a surrogate marker of HPV status in OPC.
Journal ArticleDOI
Deletion of the Tumor Suppressor NFKBIA in Triple-Negative Breast Cancer
M. Bredel,Hyunsoo Kim,T.K. Nanda,Denise M. Scholtens,Pierre A. Robe,S.I. Branimir,James A. Bonner +6 more
Journal ArticleDOI
NFKBIA deletion in triple-negative breast cancer.
Markus Bredel,Hyunsoo Kim,Nanda K. Thudi,Denise M. Scholtens,James A. Bonner,Branimir I. Sikic +5 more
TL;DR: The mainstay treatment for triple-negative breast cancer is chemotherapy with or without a priorectomy, and target-directed therapies for both ER-positive and HER2-amplified breast cancer are indicated.
Journal ArticleDOI
Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734
Michael C. Perry,Leslie J. Kohman,James A. Bonner,Lin Gu,Xiaofei Wang,Everett E. Vokes,Mark R. Green +6 more
TL;DR: Post-operative RT may decrease local recurrence but has not been shown to improve survival, and surgical therapy for selected stage IIIA NSCLC patients yields 5-year survival of 15–30%.
Journal ArticleDOI
A phase I/II trial of induction chemotherapy followed by concomitant docetaxel with concomitant boost radiotherapy (CBR) and amifostine for advanced head and neck cancer (HNC)
C. Saurel,Ruby F. Meredith,James A. Bonner,Glenn E. Peters,William R. Carroll,Sharon A. Spencer,Lisle Nabell +6 more
TL;DR: Responsibility to induction chemotherapy was greater then 75% by radiological assessment, with no patient developing distant metastasis thus far, and this aggressive therapy is effective treatment for locally advanced SCCHN.